

Paweł, Robak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5304883/publications.pdf>

Version: 2024-02-01

61
papers

1,636
citations

361413

20
h-index

302126

39
g-index

61
all docs

61
docs citations

61
times ranked

2473
citing authors

#	ARTICLE	IF	CITATIONS
1	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	10.7	254
2	Drug resistance in multiple myeloma. <i>Cancer Treatment Reviews</i> , 2018, 70, 199-208.	7.7	200
3	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	13.7	188
4	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. <i>Drugs in R and D</i> , 2019, 19, 73-92.	2.2	98
5	Older and new purine nucleoside analogs for patients with acute leukemias. <i>Cancer Treatment Reviews</i> , 2013, 39, 851-861.	7.7	78
6	Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. <i>Molecules</i> , 2009, 14, 1183-1226.	3.8	66
7	BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. <i>International Reviews of Immunology</i> , 2013, 32, 358-376.	3.3	42
8	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41
9	Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2009, 69, 2415-2449.	10.9	39
10	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1383-90.	2.3	35
11	Purine Nucleoside Analogs in the Treatment of Rarer Chronic Lymphoid Leukemias. <i>Current Pharmaceutical Design</i> , 2012, 18, 3373-3388.	1.9	33
12	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2022, 9, e98-e110.	4.6	32
13	Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. <i>Haematologica</i> , 2015, 100, e207-e210.	3.5	31
14	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1249-1265.	4.1	31
15	The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2008, 49, 1452-1462.	1.3	29
16	OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. <i>Future Oncology</i> , 2020, 16, 631-641.	2.4	28
17	Anti-CD37 antibodies for chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 651-661.	3.1	27
18	Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 280-290.	2.2	25

#	ARTICLE	IF	CITATIONS
19	Current treatment options in prolymphocytic leukemia. <i>Medical Science Monitor</i> , 2007, 13, RA69-80.	1.1	24
20	A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia. <i>Current Medicinal Chemistry</i> , 2012, 19, 5294-5318.	2.4	22
21	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	2.5	21
22	The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. <i>Cancers</i> , 2020, 12, 2569.	3.7	21
23	Emerging antibody-drug conjugates for treating lymphoid malignancies. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 259-273.	2.4	20
24	Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1529-1543.	2.4	19
25	Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	3.0	18
26	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. <i>Advances in Medical Sciences</i> , 2019, 64, 349-355.	2.1	16
27	High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement. <i>Leukemia and Lymphoma</i> , 2006, 47, 1667-1669.	1.3	14
28	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. <i>Leukemia and Lymphoma</i> , 2004, 45, 1261-1267.	1.3	13
29	Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2006, 47, 2625-2634.	1.3	13
30	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	1.3	13
31	Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2622-2634.	1.3	13
32	Bone lesions in hairy cell leukemia: Diagnosis and treatment. <i>European Journal of Haematology</i> , 2020, 105, 682-691.	2.2	12
33	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	4.1	11
34	Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. <i>European Journal of Cancer</i> , 2014, 50, 2677-2684.	2.8	10
35	Potential breakthroughs with investigational drugs for hairy cell leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1419-1431.	4.1	10
36	Emerging immunological drugs for chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 423-447.	2.4	9

#	ARTICLE	IF	CITATIONS
37	The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. <i>Cancers</i> , 2021, 13, 951.	3.7	9
38	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	2.2	8
39	Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. <i>BioDrugs</i> , 2016, 30, 87-93.	4.6	7
40	Toward personalized therapy for chronic lymphocytic leukemia. <i>Cancer Biology and Therapy</i> , 2013, 14, 6-12.	3.4	6
41	Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia. <i>International Journal of Oncology</i> , 2015, 46, 1259-1267.	3.3	6
42	Treatment Options for Autoimmune Cytopenias. <i>Transfusion Medicine and Hemotherapy</i> , 2004, 31, 332-340.	1.6	5
43	Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development. <i>Oncology Letters</i> , 2017, 13, 2079-2084.	1.8	5
44	MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance. <i>Current Medicinal Chemistry</i> , 2021, 28, 6753-6772.	2.4	5
45	Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. <i>Medical Oncology</i> , 2012, 29, 2111-2126.	2.5	4
46	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 527-534.	0.4	4
47	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	1.3	3
48	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	1.4	3
49	The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12070.	4.1	3
50	Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. <i>Journal of Clinical Medicine</i> , 2022, 11, 112.	2.4	3
51	Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors. <i>Molecular Medicine Reports</i> , 2019, 19, 3593-3603.	2.4	2
52	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. <i>Haematologica</i> , 2021, 106, 601-604.	3.5	2
53	Multifocal osteolytic lesions in hairy cell leukemia—the importance of PET/CT in diagnosis and assessment. <i>Annals of Hematology</i> , 2021, 100, 1641-1645.	1.8	2
54	ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 8001-8001.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. <i>Journal of Clinical Medicine</i> , 2021, 10, 5028.	2.4	1
56	New Therapies for Patients with Chronic Lymphocytic Leukemia. <i>Current Cancer Therapy Reviews</i> , 2008, 4, 235-242.	0.3	0
57	Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro. <i>Journal of Chemistry</i> , 2015, 2015, 1-11.	1.9	0
58	Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 89-128.	0.1	0
59	Cytotoxic Effect of R-Etodolac (SDX-101) in Combination with Purine Analogues or Monoclonal Antibodies on Ex-Vivo B-Cell Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2005, 106, 2122-2122.	1.4	0
60	Usefulness of Differential Scanning Calorimetry for Monitoring Ex Vivo the Changes In Responses of CLL Cells to Anti-Cancer Drugs: Development of Personalized Therapy. <i>Blood</i> , 2010, 116, 4635-4635.	1.4	0
61	New Therapies for Chronic Lymphocytic Leukemia. <i>Current Cancer Therapy Reviews</i> , 2014, 9, 245-257.	0.3	0